May 2024 PLAB Guidelines: Cardio & Resp | MedRevisions

What changed

• At the time of publication (May 2024), the acute coronary syndrome pathway had been refreshed with updated antiplatelet and anticoagulation sequencing per NICE guidance.
• Asthma stepwise management was aligned to the latest BTS/SIGN position at that time, including updated biologic therapy positioning.
• Heart failure pharmacological ladder was updated with clearer SGLT2 inhibitor positioning and monitoring requirements, ahead of their becoming standard of care regardless of diabetes status.

Why it matters for your score

• This article is preserved as a record of the May 2024 editorial update. UK cardiology and respiratory guidance continues to evolve — especially the positioning of SGLT2 inhibitors and asthma biologics.
• For your revision, rely on the current in-app expert note (check the 'last reviewed' date) rather than the specific claims in this dated article.

Practical checklist

• Open the current heart failure and ACS notes in-app and verify the 'last reviewed' date.
• Cross-check your personal revision notes against those live in-app notes.
• If you find a discrepancy with this historical article, trust the in-app note and flag the article.